Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARD-101 in Prader-Willi Syndrome
NCT07197034Phase 3Terminated
- Sponsor
- Aardvark Therapeutics, Inc.
- Start
- Jul 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of ARD-101 in Prader-Willi syndrome (PWS), sponsored by Aardvark Therapeutics, Inc.. Started Jul 2024; status: terminated.
02
Drugs
ARD-101
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NCT07197034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07197034.